What happens when you stop taking a GLP-1 drug?
The short answer is that the benefits—especially weight loss and blood sugar control—are not permanent. These drugs work by mimicking a hormone that slows digestion and signals fullness, so when you stop taking them, those effects wear off. A mega-analysis of over 10,000 clinical trials [2] explicitly states that weight loss from GLP-1 drugs like semaglutide and tirzepatide is not sustained after discontinuation. In practical terms, most people regain the weight they lost within months of stopping.
The same pattern applies to blood sugar control. A large 2025 study [1] that tracked over 215,000 people with diabetes on GLP-1 drugs found that the reduced risk of heart disease, kidney problems, and other complications was linked to ongoing use. Once the drug is stopped, those protective effects fade. The study did not report outcomes after discontinuation, but the implication is clear: the benefits are drug-dependent.
Are there any lasting effects after stopping?
Some effects may persist, but they are mostly negative. For example, a 2022 study [3] found that people who used GLP-1 drugs for 1–3 years had a 58% higher risk of thyroid cancer (all types) and a 78% higher risk of medullary thyroid cancer. This risk was seen during treatment and may not reverse after stopping, because cancer development takes time. Similarly, a case report [4] describes a patient whose severe gastroparesis (stomach paralysis) was triggered by switching to semaglutide and did not resolve after stopping the drug—she was advised never to take a GLP-1 again.
On the positive side, a 2021 study [5] found that GLP-1 receptor activation may shift immune cells toward a protective type (M2 macrophages) that reduces artery plaque. This effect could theoretically persist after stopping, but the study only measured it during treatment, so it's unclear how long it lasts. Overall, the evidence for lasting positive benefits is weak, while the evidence for lasting risks is stronger.
Does tirzepatide (Mounjaro) behave differently?
Tirzepatide, which combines GLP-1 and GIP effects, is more potent for weight loss and blood sugar control than semaglutide alone. A 2026 review [6] found that tirzepatide produced greater HbA1c reductions (over 2%) and more weight loss, and these benefits were 'maintained in the long term'—but only with continued use. The review also noted that side effects like nausea and vomiting are most common in the first weeks and decrease over time, but again, this is during active treatment. No study in this set shows that tirzepatide's benefits persist after stopping.
About These Sources
This answer is built on 6 peer-reviewed studies — published from 2021 to 2026, 4 from 2024 or later, 4 in Q1 journals, collectively cited 491 times — selected as the most relevant from 7 studies that passed quality screening, drawn from 60 papers retrieved from a database of over 500 million.
Sources used in this answer
Mapping the effectiveness and risks of GLP-1 receptor agonists
In a large cohort of 215,970 people with diabetes, GLP-1 use was associated with reduced risks of 175 health outcomes including Alzheimer's disease and heart disease, but also increased risks of gastrointestinal disorders and pancreatitis. All associations were measured during drug use.
Clinical Data Mega-Collection of Obesity and Obesity-Related Trials: Primary Inclusion Criteria from All Studies and Highlights of Clinical Efficacy Analysis of GLP-1 Drugs
A mega-analysis of over 10,000 obesity trials found that weight loss from GLP-1 drugs like semaglutide and tirzepatide is not sustained after discontinuation. The FDA's 5% weight loss threshold is met only during active treatment.
GLP-1 Receptor Agonists and the Risk of Thyroid Cancer
In a nested case-control study of 2,562 thyroid cancer cases, GLP-1 use for 1–3 years was linked to a 58% higher risk of all thyroid cancer and a 78% higher risk of medullary thyroid cancer. This risk was observed during treatment and may persist.
6486 Gastroparesis Exacerbation by a GLP-1 Agonist
A case report describes a patient with diabetic gastroparesis who developed a severe flare after two doses of semaglutide, requiring hospitalization and total parenteral nutrition. Her symptoms did not resolve after stopping the drug, and she was advised never to take a GLP-1 again.
Effect of GLP‐1/GLP‐1R on the Polarization of Macrophages in the Occurrence and Development of Atherosclerosis
In a study of 49 coronary heart disease patients, GLP-1 receptor activation was associated with a shift of macrophages toward the protective M2 type, suggesting a cardiovascular benefit independent of blood sugar control. This effect was measured during treatment.
Long-Term Safety Of Tirzepatide (Mounjaro): Relationship Between Duration Of Use And Adverse Events Compared With Semaglutide And Liraglutide
An integrative review of 32 studies found that tirzepatide produces greater HbA1c reductions (over 2%) and weight loss than GLP-1 agonists alone, with gastrointestinal side effects most common in the first weeks. Benefits were maintained long-term only with continued use.